<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001354457</cik>
        <entityName>Nasdaq Stock Market LLC</entityName>
    </exchange>

    <issuer>
        <cik>0001645666</cik>
        <entityName>Kezar Life Sciences, Inc.</entityName>
        <fileNumber>001-38542</fileNumber>
        <address>
            <street1>4000 Shoreline Court, Suite 300</street1>
            <street2></street2>
            <city>South San Francisco</city>
            <stateOrCountryCode>CA</stateOrCountryCode>
            <stateOrCountry>CALIFORNIA</stateOrCountry>
            <zipCode>94080</zipCode>
        </address>
        <telephoneNumber>(650) 822-5612</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>common stock</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(a)(3)</ruleProvision>

    <signatureData>
        <signatureName>Tara Petta</signatureName>
        <signatureTitle>AVP</signatureTitle>
        <signatureDate>2026-05-11</signatureDate>
    </signatureData>
</notificationOfRemoval>
